Fosamax Cost in Nebraska 2026: What You'll Actually Pay for Alendronate

What Does Fosamax Actually Cost in Nebraska Right Now?

Generic alendronate 70 mg costs about $15 per month at Nebraska retail pharmacies in 2026, while the brand-name Fosamax carries a list price near $80 per month. Most Nebraska patients filling a generic prescription with a GoodRx-style coupon pay between $10 and $18 depending on their pharmacy and the specific coupon used.

The wide gap between brand and generic reflects the fact that Merck's original Fosamax patent expired over a decade ago. Multiple manufacturers now produce alendronate sodium 70 mg tablets, which drives the retail cash price far below the brand list price. Walgreens, CVS, Hy-Vee, and Walmart pharmacies across Nebraska all stock generic alendronate; Walmart's $4 and $10 generic program frequently includes alendronate 70 mg on the qualifying drug list, making it one of the lowest-cost options for cash-pay patients in the state.

Brand Fosamax is rarely dispensed today. If a prescriber writes "brand only" or a patient specifically requests the Merck product, the out-of-pocket cost without insurance can reach $280 to $320 for a 30-day supply at Nebraska pharmacies. There is no clinical evidence that brand Fosamax outperforms generic alendronate at equivalent doses. The FDA's bioequivalence standards require generic formulations to fall within 80 to 125 percent of the brand's pharmacokinetic parameters, a threshold that all approved alendronate generics meet. [1]

For patients who qualify for a 503A compounded formulation (discussed later in this article), the effective out-of-pocket cost may be $0 per month, depending on how the compound is prescribed and billed.

Does Nebraska Medicaid Cover Fosamax or Generic Alendronate?

Nebraska Medicaid does not cover Fosamax or generic alendronate for the osteoporosis indication as of 2026. Patients enrolled in Nebraska's Heritage Health Medicaid managed care program who request alendronate for osteoporosis will find it is excluded from the preferred drug list (PDL) for that indication.

This creates a real access gap. Nebraska has a notably older rural population, and bisphosphonate therapy is endorsed by both the Endocrine Society and the American Association of Clinical Endocrinology (AACE) as first-line pharmacotherapy for postmenopausal osteoporosis when the 10-year FRAX probability of major osteoporotic fracture reaches 20 percent or greater, or hip fracture probability reaches 3 percent or greater. [2]

Patients on Medicaid have several potential workarounds. First, Nebraska Medicaid does cover some osteoporosis treatments, including certain injectable bisphosphonates and denosumab under specific criteria, so a prescriber can request a prior authorization or therapeutic substitution. Second, given the ~$15 generic cash price, many Medicaid patients find it cheaper to simply pay out of pocket for generic alendronate than to pursue an authorization pathway for a costlier alternative. Third, the Merck Patient Assistance Program (PAP), accessible through their NeedyMeds listing, covers uninsured and Medicaid-excluded patients who meet income thresholds. [3]

Nebraska's Medicaid formulary is reviewed annually. Advocates and prescribers can submit pharmacoeconomic evidence to request PDL inclusion; the Nebraska Department of Health and Human Services drug utilization review board meets quarterly.

Which Insurance Plans Cover Alendronate in Nebraska?

Most commercial insurance plans available in Nebraska, including those sold on the ACA marketplace through Healthcare.gov, cover generic alendronate 70 mg as a Tier 1 or Tier 2 medication. Tier 1 generics typically carry a $0 to $10 copay; Tier 2 generics run $15 to $45 depending on the plan's design.

Specific plan families available to Nebraska residents in 2026 include Blue Cross and Blue Shield of Nebraska, Medica, and UnitedHealthcare. All three cover generic alendronate on their standard formularies at the generic tier. Medicare Part D plans are a slightly different story. Coverage depends on whether a plan has included alendronate in its formulary for the benefit year; CMS requires Part D plans to cover at least two drugs in each therapeutic category, but the specific bisphosphonate selected can vary. Patients should use the Medicare Plan Finder tool at medicare.gov to compare the alendronate tier and copay before enrollment.

For employer-sponsored insurance, coverage is nearly universal. A 2023 analysis of commercial insurance claims found that alendronate was covered by more than 94 percent of commercial formularies at a generic tier. [4] That figure has not declined in 2026; if anything, the shift toward value-based formulary design has kept low-cost generics like alendronate at preferred status.

One practical tip: ask your pharmacist to run the prescription through both your insurance and a GoodRx coupon simultaneously. In some Nebraska pharmacies, the GoodRx cash price is lower than the insurance copay, particularly for patients in high-deductible plans during the deductible phase.

Is Compounded Alendronate Legal in Nebraska?

Yes. 503A compounding pharmacies licensed in Nebraska may legally prepare compounded alendronate for individual patients who have a valid prescription from a licensed prescriber. This is permitted under federal law (21 U.S.C. § 503A) and Nebraska's Pharmacy Practice Act, provided the compound is prepared in response to a patient-specific prescription and is not commercially available in an identical form. [5]

The distinction between 503A and 503B matters here. A 503A pharmacy compounds for individual patients on a prescription-by-prescription basis. A 503B outsourcing facility produces larger batches for office use without a patient-specific prescription. Nebraska has no licensed 503B outsourcing facility for alendronate as of early 2026, so all compounded alendronate in the state flows through 503A pharmacies.

Why would a patient use compounded alendronate rather than the $15 generic tablet? There are a few scenarios. Some patients have documented dysphagia or esophageal motility disorders that make swallowing a tablet problematic; a 503A pharmacy can prepare alendronate in a liquid or suspension form. Patients who have had upper GI procedures, such as Roux-en-Y gastric bypass, may have absorption concerns that warrant different formulation strategies discussed with their prescriber. A compounded formulation may also be covered under a patient's specific benefit structure in ways the commercial tablet is not, bringing the effective cost to $0.

Compounding does not change the underlying pharmacology or the clinical evidence base. The key Fracture Intervention Trial (FIT), published in JAMA in 1998, enrolled 2,027 women with low bone density and found that alendronate reduced the incidence of radiographically confirmed vertebral fractures by 47 percent (relative risk 0.53 to 95% CI 0.41 to 0.68, P<0.001) compared to placebo over three years. [6] That data was generated with the oral tablet; compounded formulations must be assumed to have equivalent efficacy only when bioavailability is preserved.

Can a Nebraska Telehealth Provider Prescribe Fosamax?

Telehealth prescribing of alendronate is permitted in Nebraska. Nebraska follows the standard telemedicine prescribing framework: a provider licensed in Nebraska may prescribe a non-controlled medication after conducting a synchronous audio-video visit that meets the standard of care for a valid patient-provider relationship. Alendronate is not a controlled substance, so the additional prescribing restrictions that apply to Schedule II through V medications do not apply. [7]

Practically, this means a Nebraska resident can schedule a telehealth visit with a HealthRX clinician, have their bone density history and FRAX score reviewed, and receive an alendronate prescription sent electronically to any Nebraska pharmacy. The prescription can be filled the same day. No in-person visit is required for an established patient receiving ongoing therapy.

The American Association of Clinical Endocrinology's 2020 clinical practice guidelines for postmenopausal osteoporosis state: "Oral bisphosphonates, including alendronate and risedronate, are recommended as first-line pharmacological therapy for most postmenopausal women with osteoporosis based on anti-fracture efficacy, safety profile, and cost." [2] That recommendation does not require in-person prescribing and is fully compatible with telehealth-based care.

One practical note for telehealth patients: DXA (dual-energy X-ray absorptiometry) scans cannot be performed remotely. Nebraska has DXA imaging at most critical-access hospitals and orthopedic clinics throughout the state, including facilities in Omaha, Lincoln, Grand Island, Kearney, and Norfolk. A telehealth prescriber may review existing DXA results or coordinate a referral for imaging before initiating therapy.

What Is the Cheapest Way to Get Fosamax in Nebraska?

The lowest reliable out-of-pocket cost for most Nebraska patients in 2026 is the Walmart $4/$10 generic program, which prices a 30-day supply of alendronate 70 mg at $4 and a 90-day supply at $10. Not every Walmart location participates identically, and the program covers the 70 mg weekly tablet, not the 10 mg daily tablet or IV formulations.

For patients who do not live near a Walmart, GoodRx and similar coupon aggregators bring the cash price to $10 to $18 at chains including Walgreens, CVS, and Hy-Vee. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) listed alendronate 70 mg at $6.60 for a 4-tablet supply as of late 2025, with free or flat-rate shipping to Nebraska addresses.

HealthRX Nebraska Alendronate Cost Decision Framework (2026)

Use this tiered approach to find your lowest-cost path:

1. Insured (commercial or Medicare Part D): Run the prescription through insurance first. If your copay exceeds $15, ask the pharmacist to price it as a cash-pay GoodRx purchase instead.
2. Medicaid enrolled: Pay the ~$15 cash price out of pocket OR ask your prescriber about a prior authorization for an alternative covered bisphosphonate.
3. Uninsured, income <250% FPL: Apply to the Merck Patient Assistance Program at pap.merck.com. Processing takes 10 to 14 business days.
4. Dysphagia or documented swallowing difficulty: Ask your prescriber about a 503A compounded liquid formulation; cost may be $0 under certain insurance structures.
5. Prefer home delivery: Order through Cost Plus Drugs or an accredited mail-order pharmacy; 90-day supply at the lowest cash price reduces per-dose cost by an additional 20 to 30 percent.

How Does the Merck Savings Card Work in Nebraska?

The Merck savings card for brand-name Fosamax is designed for commercially insured patients. Eligible Nebraska patients with private insurance can reduce their brand Fosamax copay to as low as $0 per month, subject to a maximum program benefit of $2,400 per year. The card is not valid for Medicare, Medicaid, or any other federal or state government insurance program.

Given that generic alendronate costs $10 to $15 per month in Nebraska and is therapeutically equivalent, the savings card is most relevant for patients whose prescriber has documented a specific clinical reason to use brand Fosamax, which is uncommon. Most pharmacists and prescribers in Nebraska default to the generic unless otherwise specified.

For patients who want the savings card, enrollment is available at merck.com. Nebraska residents submit proof of commercial insurance, and the card loads a discount applied at the pharmacy register. The program renews annually and may change its terms each calendar year.

Alendronate Dosing and Clinical Efficacy: What Nebraska Patients Should Know

Standard dosing is 70 mg orally once weekly for osteoporosis treatment, or 35 mg once weekly for osteoporosis prevention. The daily 10 mg tablet is approved but rarely used in practice because the once-weekly formulation achieves equivalent efficacy with better adherence. [8]

The FIT trial (N=2,027) remains the most cited efficacy anchor. Published in JAMA in 1998, FIT showed a 47 percent reduction in radiographic vertebral fractures (RR 0.53) and a 51 percent reduction in clinical vertebral fractures over three years in postmenopausal women with low femoral neck bone density. [6] Hip fracture risk fell by 51 percent in the highest-risk subgroup. These are the numbers that justify first-line use.

Adherence is a documented problem with oral bisphosphonates. A large cohort study found that fewer than 50 percent of patients remained adherent to alendronate at 12 months, and patients who took fewer than 80 percent of prescribed doses showed no statistically significant fracture reduction. [9] Once-weekly dosing improved adherence rates compared to daily dosing by roughly 15 to 20 percent in head-to-head compliance studies. Nebraska telehealth providers commonly set automated refill reminders to address this.

Administration rules are strict and affect tolerability. Patients must take alendronate with 6 to 8 ounces of plain water, remain upright for at least 30 minutes afterward, and avoid food, other beverages, and other medications for 30 minutes post-dose. These requirements protect against esophageal irritation and optimize absorption. Calcium and vitamin D supplementation should be co-prescribed; the National Osteoporosis Foundation recommends 1,000 to 1 to 200 mg of calcium daily (from diet and supplements combined) and 800 to 1 to 000 IU of vitamin D3 daily for patients on bisphosphonate therapy. [10]

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures are rare but real adverse events. ONJ risk is estimated at fewer than 1 per 10,000 patient-years for oral alendronate at osteoporosis doses, according to an American Society for Bone and Mineral Research task force report. [11] Risk increases substantially with IV bisphosphonate therapy for oncologic indications, which is a different clinical context. Nebraska patients should inform their dentist of alendronate use before invasive dental procedures.

Drug holidays after 3 to 5 years of therapy are an area of active clinical discussion. The FLEX trial showed that patients who discontinued alendronate after 5 years maintained bone density and fracture protection for up to 5 additional years if their femoral neck T-score was above minus 2.5 at discontinuation. [12] Whether to take a holiday, and when to restart, is a decision best made with the prescribing clinician based on current DXA data and FRAX score.

Nebraska-Specific Access Considerations

Nebraska's geography shapes how patients access alendronate. Roughly 30 percent of Nebraska residents live in rural counties classified as Health Professional Shortage Areas (HPSAs) for primary care. Rural patients face longer travel times to DXA imaging and endocrinology consultations, making telehealth an especially practical channel for ongoing prescription management.

Nebraska has no state-level osteoporosis screening mandate beyond the federally required Medicare coverage for DXA in women aged 65 and older and in younger women with documented risk factors. The U.S. Preventive Services Task Force gives a B recommendation to screening with bone measurement testing in women 65 years or older and in younger postmenopausal women whose 10-year fracture risk is equal to or greater than that of a 65-year-old white woman with no additional risk factors. [13]

For Nebraska patients who have already been diagnosed with osteoporosis and are stable on alendronate, annual telehealth check-ins combined with DXA imaging every 1 to 2 years represent a clinically sound and cost-effective monitoring model. The prescription itself, at $10 to $15 per month generic cash price or covered at Tier 1 by most commercial plans, is rarely the primary cost driver. Imaging and clinician time are usually larger line items for Nebraska patients who lack insurance.